Precision BioSciences
DTIL
76 hedge funds and large institutions have $11.8M invested in Precision BioSciences in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 12 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
0.28% less ownership
Funds ownership: 1.28% → 1% (-0.28%)
1% less funds holding
Funds holding: 77 → 76 (-1)
49% less capital invested
Capital invested by funds: $23M → $11.8M (-$11.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$330K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$327K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$216K |
| 4 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$169K |
| 5 |
Goldman Sachs
New York
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.93M |
| 2 |
JP Morgan Chase
New York
|
-$857K |
| 3 |
CA
CHI Advisors
New York
|
-$511K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$247K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$223K |
DTIL Hedge Fund Activity: Q3 2023 in Review
76 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q3 2023, worth a combined $11.8M — down 49% from $23M a quarter earlier.
Fund positioning in DTIL was balanced in Q3 2023: 12 funds opened new positions, 12 closed out, 19 added to existing stakes and 16 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $330K. The largest seller was Great Point Partners, exiting entirely with an estimated $3.93M sold.
- 76 institutional investors held Precision BioSciences (DTIL) as of Q3 2023, down from 77 in Q2 2023.
- Funds reported $11.8M of Precision BioSciences stock for Q3 2023, down 49% quarter-over-quarter.
- 12 funds opened new Precision BioSciences positions in Q3 2023 and 12 closed out, a net change of 0 holders.
- The largest Precision BioSciences buyer in Q3 2023 was Jacobs Levy Equity Management, an estimated $330K added.
- The largest Precision BioSciences seller in Q3 2023 was Great Point Partners, an estimated $3.93M sold.
Based on aggregated 13F filings for Q3 2023.